We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Study Highlights Importance of Regular Lung Cancer Screenings for Higher Risk Patients

By LabMedica International staff writers
Posted on 29 Aug 2016
Researchers have found that patients who tested negative for lung cancer (LC) in an LDCT (low-dose helical computed tomography) screening, but later went on to develop lung cancer within the following two years, had poorer outcomes than patients who initially had a non-cancerous positive screen test result.

Lung cancer is one of the most complex cancers, both at the molecular level and through its clinical behavior. More...
Based on the large randomized “National Lung Screening Trial” study, the US Preventive Services Task Force recommends regular LC screenings with LDCT for people between ages 55-74 who have smoked at least one pack of cigarettes per day for 30 years or more. The recommendations also include heavy smokers who have quit within the past 15 years.

The new study, by researchers at the H. Lee Moffitt Cancer Center & Research Institute (Tampa, FA, USA), used the data from the National Lung Screening Trial to determine the outcomes of patients screened by LDCT according to their initial 12- and 24-month screening results. They found that patients who had a negative initial screening but tested positive for lung cancer at the 12- or 24-month screen had lower survival and higher mortality rates than patients who had a positive initial screen that was a non-cancerous abnormality but developed lung cancer in subsequent screens.

“Our findings suggest that individuals who originally present with negative screens and develop lung cancer 12 or 24 months later develop faster growing, more aggressive cancers that arose from a lung environment previously lacking abnormalities,” said Matthew B. Schabath, PhD, of Moffitt’s Cancer Epidemiology Program. The data also highlight the importance of continued lung cancer screening in high-risk patients. “Although tobacco cessation is one of the most important ways to reduce your risk of lung cancer, screening is a proven method to detect lung cancer earlier when it is easier to treat. Moreover, screening is not a one-time event. For it to be effective, high-risk individuals need to be screened on regular yearly intervals,” said Dr. Schabath.

The study, by Schabath MB et al, was published August 10, 2016, in the journal PLOS One.

Related Links:
H. Lee Moffitt Cancer Center & Research Institute



New
Gold Member
Automatic Hematology Analyzer
DH-800 Series
Collection and Transport System
PurSafe Plus®
New
Sample Transportation System
Tempus1800 Necto
New
Sperm Quality Analyis Kit
QwikCheck Beads Precision and Linearity Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New research points to protecting blood during radiation therapy (Photo courtesy of 123RF)

Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments

Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more

Immunology

view channel
Image: The VENTANA HER2 (4B5) test is now CE-IVDR approved (Photo courtesy of Roche)

Companion Diagnostic Test Identifies HER2-Ultralow Breast Cancer and Biliary Tract Cancer Patients

Breast cancer is the most common cancer in Europe, with more than 564,000 new cases and 145,000 deaths annually. Metastatic breast cancer is rising in younger populations and remains the leading cause... Read more

Technology

view channel
Image: Conceptual design of the CORAL capsule for microbial sampling in the small intestine (H. Mohammed et al., Device (2025). DOI: 10.1016/j.device.2025.100904)

Coral-Inspired Capsule Samples Hidden Bacteria from Small Intestine

The gut microbiome has been linked to conditions ranging from immune disorders to mental health, yet conventional stool tests often fail to capture bacterial populations in the small intestine.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.